151 related articles for article (PubMed ID: 38672597)
1. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Legoux JL; Faroux R; Barrière N; Le Malicot K; Tougeron D; Lorgis V; Guerin-Meyer V; Bourgeois V; Malka D; Aparicio T; Baconnier M; Lebrun-Ly V; Egreteau J; Khemissa Akouz F; Terme M; Lepage C; Boige V
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672597
[TBL] [Abstract][Full Text] [Related]
2. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Aparicio T; Lavau-Denes S; Phelip JM; Maillard E; Jouve JL; Gargot D; Gasmi M; Locher C; Adhoute X; Michel P; Khemissa F; Lecomte T; Provençal J; Breysacher G; Legoux JL; Lepère C; Charneau J; Cretin J; Chone L; Azzedine A; Bouché O; Sobhani I; Bedenne L; Mitry E;
Ann Oncol; 2016 Jan; 27(1):121-7. PubMed ID: 26487578
[TBL] [Abstract][Full Text] [Related]
4. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Dahan L; Bonnetain F; Ychou M; Mitry E; Gasmi M; Raoul JL; Cattan S; Phelip JM; Hammel P; Chauffert B; Michel P; Legoux JL; Rougier P; Bedenne L; Seitz JF;
Gut; 2010 Nov; 59(11):1527-34. PubMed ID: 20947887
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Maiello E; Gebbia V; Giuliani F; Paoletti G; Gebbia N; Cigolari S; Fortunato S; Pedicini T; Borsellino N; Lopez M; Colucci G
Ann Oncol; 2000 Aug; 11(8):1045-51. PubMed ID: 11038044
[TBL] [Abstract][Full Text] [Related]
8. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
10. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
[TBL] [Abstract][Full Text] [Related]
11. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
12. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Bouché O; Raoul JL; Bonnetain F; Giovannini M; Etienne PL; Lledo G; Arsène D; Paitel JF; Guérin-Meyer V; Mitry E; Buecher B; Kaminsky MC; Seitz JF; Rougier P; Bedenne L; Milan C;
J Clin Oncol; 2004 Nov; 22(21):4319-28. PubMed ID: 15514373
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cleary JM; Horick NK; McCleary NJ; Abrams TA; Yurgelun MB; Azzoli CG; Rubinson DA; Brooks GA; Chan JA; Blaszkowsky LS; Clark JW; Goyal L; Meyerhardt JA; Ng K; Schrag D; Savarese DMF; Graham C; Fitzpatrick B; Gibb KA; Boucher Y; Duda DG; Jain RK; Fuchs CS; Enzinger PC
Cancer; 2019 Jul; 125(13):2213-2221. PubMed ID: 30913304
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
Chibaudel B; Bachet JB; André T; Auby D; Desramé J; Deplanque G; Lecaille C; Louvet C; Tournigand C; Lebrun-Ly V; Dauba J; Lledo G; Garcia ML; Dubreuil O; Hamed NB; Meurisse A; Larsen AK; Tijeras-Raballand A; Bonnetain F; De Gramont A
Int J Oncol; 2019 Apr; 54(4):1433-1445. PubMed ID: 30720091
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Pernot S; Pellerin O; Mineur L; Monterymard C; Smith D; Lapuyade B; Gallois C; Khemissa Akouz F; De Baere T; Tougeron D; Thirot-Bidault A; Audemar F; Simon M; Lecaille C; Louafi S; Lepage C; Ducreux M; Taieb J
Dig Liver Dis; 2022 Mar; 54(3):324-330. PubMed ID: 35027324
[TBL] [Abstract][Full Text] [Related]
19. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
